National Academies Press: OpenBook
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×

Government and Industry Collaboration in AIDS Drug Development

Summary of a Workshop Held on May 6, 1994

Leslie M. Hardy, Editor

Roundtable for the Development of Drugs and Vaccines Against AIDS

Division of Health Promotion and Disease Prevention

INSTITUTE OF MEDICINE

NATIONAL ACADEMY PRESS
Washington, D.C.
1994

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×

National Academy Press
2101 Constitution Avenue, NWWashington, DC20418

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance.

This workshop summary was prepared by the Institute of Medicine's Roundtable for the Development of Drugs and Vaccines Against AIDS, chaired by Barton F. Haynes and Paul A. Volberding and directed by Leslie M. Hardy. The document reports major themes of the workshop discussions; these themes, however, do not represent policy statements by the Institute of Medicine.

The report has been reviewed by a group other than the authors according to procedures approved by a Report Review Committee consisting of members of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

The Institute of Medicine was chartered in 1970 by the National Academy of Sciences to enlist distinguished members of appropriate professions in the examination of policy matters pertaining to the health of the public. In this, the Institute acts under both the Academy's 1863 congressional charter responsibility to be an advisor to the federal government and its own initiative in identifying issues of medical care, research, and education. Dr. Kenneth I. Shine is president of the Institute of Medicine.

The Roundtable is supported by the American Foundation for AIDS Research, the Pharmaceutical Research and Manufacturers of America, the U.S. Army, the U.S. Public Health Service, and the U.S. Department of Veterans Affairs.

Additional copies of this report are available in limited quantities from:

Division of Health Promotion and Disease Prevention

Institute of Medicine

2101 Constitution Avenue, NW

Washington, DC 20418

(202) 334-2453

Copyright1994by theNational Academy of Sciences. All rights reserved.

Printed in the United States of America.

The serpent has been a symbol of long life, healing, and knowledge among almost all cultures and religions since the beginning of recorded history. The image adopted as a logotype by the Institute of Medicine is based on a relief carving from ancient Greece, now held by the Staatlichemuseen in Berlin.

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×

ROUNDTABLE FOR THE DEVELOPMENT OF DRUGS AND VACCINES AGAINST AIDS

BARTON F. HAYNES (Cochair), F.M. Hanes Professor of Medicine,and Director,

Duke University Arthritis Center, Duke University School of Medicine, Durham, North Carolina

PAUL A. VOLBERDING (Cochair), Chief,

AIDS Program and Clinical Oncology, San Francisco General Hospital, San Francisco, California

JAMES ALLEN, Vice President,

Group on Science Technology and Public Health, American Medical Association, Chicago, Illinois

ARTHUR J. AMMANN, Director,

The Ariel Project for the Prevention of HIV Transmission from Mother to Infant, Novato, California

DAVID BARR, Director,

Treatment Education and Advocacy, Gay Men's Health Crisis, New York, New York

DAVID W. BARRY, Group Director,

Research, Development and Medical Affairs, The Wellcome Research Laboratories, Research Triangle Park, North Carolina

LAWRENCE S. BROWN, Assistant Clinical Professor of Medicine,

College of Physicians and Surgeons, Columbia University, and Senior Vice President, Addiction Research and Treatment Corporation, Brooklyn, New York

DONALD S. BURKE, Colonel,

Medical Corps, U.S. Army, and Director, Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, Maryland

BRUCE A. CHABNER, Director,

Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

MAX D. COOPER, Investigator,

Howard Hughes Medical Institute, Professor of Medicine, Pediatrics, and Microbiology, University of Alabama, Birmingham

MARTIN DELANEY, Founding Director,

Project Inform, San Francisco, California

R. GORDON DOUGLAS, Vice President,

Merck & Co., Inc., and President, Merck Vaccine Division, Merck & Co., Inc., Whitehouse Station, New Jersey

ANTHONY S. FAUCI, Director,

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

DAVID FEIGAL, Director,

Division of Antiviral Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland

GERALD FRIEDLAND, Director,

AIDS Program, Yale University School of Medicine, Yale-New Haven Hospital, New Haven, Connecticut

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×

L. PATRICK GAGE, Chief Operating Officer,

Genetics Institute, Inc., Cambridge, Massachusetts

KRISTINE M. GEBBIE, First National AIDS Policy Coordinator,

Executive Office of the President, Washington, D.C.

PETER BARTON HUTT, Partner,

Covington & Burling, Washington, D.C.

STEPHEN W. LAGAKOS, Professor of Biostatistics,

Harvard School of Public Health, Boston, Massachusetts

HELEN RODRIGUEZ-TRIAS, Pediatric Consultant in Health Programming,

Brookdale, California

CATHERINE M. WILFERT, Professor of Pediatrics and Microbiology,

Department of Pediatrics, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina

Institute of Medicine Staff

LESLIE M. HARDY, Project Director

JENNIFER K. HOLLIDAY, Project Assistant

MICHAEL A. STOTO, Director,

Division of Health Promotion and Disease Prevention

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×

WORKSHOP SPEAKERS

DAVID W. BARRY, Group Director,

Research, Development and Medical Affairs, The Wellcome Research Laboratories, Research Triangle Park, North Carolina

STEPHEN K. CARTER, Senior Vice President,

World Wide Clinical Research & Development, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey

BRUCE A. CHABNER, Director,

Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

MARTIN DELANEY, Founding Director,

Project Inform, San Francisco, California

HAROLD EDGAR, Professor of Law,

Columbia University School of Law, New York, New York

ANTHONY S. FAUCI, Director,

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

L. PATRICK GAGE, Chief Operating Officer,

Genetics Institute, Inc., Cambridge, Massachusetts

BARTON F. HAYNES, F.M. Hanes Professor of Medicine, and Director,

Duke University Arthritis Center, Durham, North Carolina

DANIEL HOTH, Senior Vice President and Chief Medical Officer,

Cell Genesys, Foster City, California

PETER BARTON HUTT, Partner,

Covington & Burling, Washington, D.C.

THOMAS MAYS, Director,

Office of Technology Development, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

DAVID SCHULKE, Chief Health Policy Advisor,

The Honorable Ron Wyden, U.S. House of Representatives, Member, Energy and Commerce Committee, Health and Environment Subcommittee, Washington, D.C.

PAUL A. VOLBERDING, Chief,

AIDS Program and Clinical Oncology, San Francisco General Hospital, San Francisco, California

TIMOTHY WESTMORELAND, Counsel,

Subcommittee on Health and the Environment, U.S. House of Representatives, Washington, D.C.

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×

PARTICIPANTS

MOISES AGOSTO, Research and Treatment Advocacy Manager,

Department of Public Policy, National Minority AIDS Council, Washington, D.C.

PAUL BLAKE, Vice Presidentand Medical Director,

Clinical Research, Development & Medical Affairs of North America, SmithKline Beecham, King of Prussia, Pennsylvania

QUETA BOND, President,

The Burroughs Wellcome Fund, Morrisville, North Carolina

BEN CHENG,

Information Advocacy Associate, Project Inform, San Francisco, California

CHARLES CHESSON, Clinical Trials Director,

SEARCH Alliance, Los Angeles, California

DEBORAH COTTON, Assistant Professor of Medicine,

Harvard Medical School, Boston, Massachusetts

RICHARD CROUT, Former Vice President,

Boehringer Mannheim Pharmaceuticals Corporation, and Institute of Medicine Scholar-in-Residence, Bethesda, Maryland

JOSEPH DIMASI, Senior Research Fellow,

Center for the Study of Drug Development, Tufts University, Boston, Massachusetts

DINO DINA, President,

Biocine Company, Chiron Corporation, Emeryville, California

CAROLYN FULCO, Study Director,

Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine, Washington, D.C.

ROBERT GOLDBERG, Senior Research Fellow,

Gordon Public Policy Center, Brandeis University, Springfield, New Jersey

LEWIS GROSSMAN, Associate,

Covington & Burling, Washington, D.C.

MARGARET JOHNSTON, Deputy Director,

Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

JACK KILLEN, Director,

Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

BARBARA MCGAREY, Deputy Director,

Office of Technology Transfer, National Institutes of Health, Bethesda, Maryland

TERESA MCGOVERN, Legal Director,

HIV Law Project, AIDS Service Center, Lower Manhattan, New York

JEAN MCKAY, Public Health Specialist,

Office of AIDS and Special Health Issues, Food and Drug Administration, Rockville, Maryland

HARRY MEYER, Former President,

Medical Research Division, American Cyanamid Company, Waterford, Virginia

CHARLES NELSON, Treatment and Research Advocate,

Department of Public Policy, National Minority AIDS Council, Washington, D.C.

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×

JOHN PALENICEK, Legislative Health Policy Fellow,

Committee on Labor and Human Resources, U.S. Senate, Washington, D.C.

WILLIAM PAUL, Director,

Office of AIDS Research, National Institutes of Health, Bethesda, Maryland

RICHARD RETTIG, Study Director,

Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine, Washington, D.C.

ZEDA ROSENBERG, Assistant Director for Prevention Research,

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

MICHAEL SAAG, Associate Professor of Medicine,

University of Alabama at Birmingham

WHAIJEN SOO, Assistant Vice President and Senior Director,

Clinical Virology and AIDS Research, Hoffmann-La Roche, Inc., Nutley, New Jersey

PETER STALEY, Founding Director,

Treatment Action Group, New York, New York

PAUL TRAN, Research Cluster Head,

Office of the National AIDS Policy Coordinator, U.S. Department of Health and Human Services, Washington, D.C.

Page viii Cite
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×

Acronyms and Abbreviations

ACTG

AIDS Clinical Trials Group

AIDS

Acquired immune deficiency syndrome

AZT

Zidovudine

CRADA

Cooperative Research and Development Agreement

CTA

Clinical Trial Agreement

ddI

Didanosine

DHHS

U.S. Department of Health and Human Services

GAO

U.S. General Accounting Office

HEW

U.S. Department of Health, Education, and Welfare

HIV

Human immunodeficiency virus

ICC

Inter-Company Collaboration for AIDS Drug Development

IP

Intellectual property

IPA

Institutional Patent Agreement

NCI

National Cancer Institute

NIH

National Institutes of Health

PHS

U.S. Public Health Service

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×

Preface

The Roundtable for the Development of Drugs and Vaccines Against AIDS was established in 1988 by the Institute of Medicine. Composed of leaders from government, the pharmaceutical industry, academia, and patient advocacy groups, its mission is to identify and help resolve impediments to the rapid availability of safe, effective drugs and vaccines for human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS). The Roundtable accomplishes its mission through regular meetings of its membership, during which urgent issues are identified and discussed, as well as through public conferences and workshops that explore scientific and policy matters central to the development of AIDS therapeutics. This report is a summary of a workshop held on May 6, 1994, in Washington, D.C.

The purpose of the workshop was to examine the challenges and opportunities inherent in government and industry collaborations on HIV/AIDS research and therapeutic development. Many of the concerns and suggestions that surfaced during the workshop deliberations, however, have broad applications beyond the field of HIV/AIDS drug development. Workshop participants explored some of the current impediments to collaboration; the implications for progress toward the discovery of novel therapeutic candidates and their development into marketed products, particularly when barriers that discourage or prevent collaborative research may exist; and ways to overcome existing obstacles. A variety of perspectives on these issues was presented, including those of government researchers and administrators, the pharmaceutical industry, the biomedical and clinical research communities, congressional staff, and consumer advocates.

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×

This report is not a consensus document but rather a synthesis of selected scientific or public policy aspects of the workshop presentations and discussions. It contains no recommendations or conclusions, and the Roundtable has neither altered nor commented on the views and opinions expressed by the speakers except for purposes of clarity. The Roundtable and staff wish to thank our consultant, Tom Burroughs, for his able assistance in preparing this summary. We also thank, once again, the workshop speakers for their thoughtful presentations and all participants for the lively, provocative discussions throughout the workshop.

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×
Page R1
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×
Page R2
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×
Page R3
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×
Page R4
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×
Page R5
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×
Page R6
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×
Page R7
Page viii Cite
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×
Page R8
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×
Page R9
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1994. Government and Industry Collaboration in AIDS Drug Development. Washington, DC: The National Academies Press. doi: 10.17226/9196.
×
Page R10
Next: CONTENTS »
Government and Industry Collaboration in AIDS Drug Development Get This Book
×
MyNAP members save 10% online.
Login or Register to save!
  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!